Todd Watanabe sold stock worth $74,892, marking a notable insider transaction amid ongoing company developments.
Arcutis Biotherapeutics CEO Todd Watanabe sold $74,892 worth of company stock, according to recent filings. The transaction reflects a routine insider move but draws attention given the company’s focus on dermatology drug development.
Prior insider activity at Arcutis has been limited, with no comparable sales reported in the last quarter. The company’s stock performance has been volatile, influenced by clinical trial updates and FDA interactions.
No immediate market reaction was observed following the disclosure, though insider transactions often prompt investor scrutiny in biotech sectors.